Allergan Launches Juvéderm® VOLITE - An Innovative Injectable Treatment Designed to Improve Skin Quality for up to 9 Months
Dublin (ots/PRNewswire) - -- Allergan enters skin quality category with new injectable product using VYCROSS® technology for use on the face, neck, décolletage and hands
-- Hyaluronic Acid (HA) gel designed to improve skin's smoothness (absence of fine lines), hydration and elasticity for up to nine months with just one treatment
-- Global research shows more than half of women say appearance of skin contributes to their outer beauty
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today its entry into the skin quality category with the launch of Juvéderm® VOLITE. This is Allergan's first injectable product specifically designed to improve skin quality and last up to nine months with just one treatment session. This innovative new Allergan product uses the unique patented VYCROSS® technology.
A new innovation for skin quality
The new HA injectable treatment delivers improvements in skin smoothness (absence of fine lines), hydration and elasticity, and is designed to last for up to nine months with just one treatment. Clinical data so far has shown significant improvements in skin quality for up to 6 months, and the clinical study is ongoing., Juvéderm® VOLITE aims to deliver results that last and eliminate the need for multiple treatments. It should be injected intradermally and can be used to treat the face, neck, décolletage and hands and contains the anaesthetic lidocaine, to enhance patient comfort.
Dr Patricia Ogilvie, Leading Dermatologist, Germany, says: "Juvéderm® VOLITE answers a real need for a treatment that delivers a healthy-looking glow. Combined with the fact that only one treatment is needed to achieve results, this product will be a game changer in my clinic. I believe that great skin can have a profound impact on patients' everyday lives - in particular their confidence. It goes far beyond aesthetics - when a patient is happy with how they look on the outside, this affects how they feel on the inside. Juvéderm® VOLITE is a genuinely innovative treatment option that I'm excited to be able to offer my patients."
For more information and to read the rest of this press release please go to: http://www.allergan.com/news/news/allergan-launches-juvederm-volite
Contact: Janet Kettels, +44-7738-506-476 Karen Dennehy, +44-7824-017-950